chr3-138946187-G-C
Variant summary
Our verdict is Benign. Variant got -20 ACMG points: 0P and 20B. BP4_StrongBP6_Very_StrongBA1
The NM_023067.4(FOXL2):āc.536C>Gā(p.Ala179Gly) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0422 in 1,488,784 control chromosomes in the GnomAD database, including 5,631 homozygotes. In-silico tool predicts a benign outcome for this variant. 14/19 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Benign (ā ā ).
Frequency
Consequence
NM_023067.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Benign. Variant got -20 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
FOXL2 | NM_023067.4 | c.536C>G | p.Ala179Gly | missense_variant | 1/1 | ENST00000648323.1 | NP_075555.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
FOXL2 | ENST00000648323.1 | c.536C>G | p.Ala179Gly | missense_variant | 1/1 | NM_023067.4 | ENSP00000497217.1 |
Frequencies
GnomAD3 genomes AF: 0.123 AC: 18681AN: 151600Hom.: 2748 Cov.: 33
GnomAD3 exomes AF: 0.0458 AC: 4117AN: 89912Hom.: 282 AF XY: 0.0492 AC XY: 2512AN XY: 51022
GnomAD4 exome AF: 0.0329 AC: 44026AN: 1337072Hom.: 2871 Cov.: 32 AF XY: 0.0341 AC XY: 22516AN XY: 659490
GnomAD4 genome AF: 0.124 AC: 18749AN: 151712Hom.: 2760 Cov.: 33 AF XY: 0.122 AC XY: 9052AN XY: 74136
ClinVar
Submissions by phenotype
not specified Benign:2
Benign, criteria provided, single submitter | clinical testing | Eurofins Ntd Llc (ga) | Mar 14, 2017 | - - |
Benign, criteria provided, single submitter | clinical testing | PreventionGenetics, part of Exact Sciences | - | - - |
not provided Benign:2
Benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 31, 2024 | - - |
Benign, criteria provided, single submitter | not provided | Breakthrough Genomics, Breakthrough Genomics | - | - - |
Blepharophimosis, ptosis, and epicanthus inversus syndrome Benign:1
Benign, criteria provided, single submitter | clinical testing | Genomic Diagnostic Laboratory, Division of Genomic Diagnostics, Children's Hospital of Philadelphia | Nov 03, 2016 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at